Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 315

1.

Dosage adjustment of anti-tumor necrosis factor-α inhibitor in ankylosing spondylitis is effective in maintaining remission in clinical practice.

Paccou J, Baclé-Boutry MA, Solau-Gervais E, Bele-Philippe P, Flipo RM.

J Rheumatol. 2012 Jul;39(7):1418-23. doi: 10.3899/jrheum.111337. Epub 2012 Jun 15.

PMID:
22707611
[PubMed - indexed for MEDLINE]
2.

Baseline predictors of response and discontinuation of tumor necrosis factor-alpha blocking therapy in ankylosing spondylitis: a prospective longitudinal observational cohort study.

Arends S, Brouwer E, van der Veer E, Groen H, Leijsma MK, Houtman PM, Th A Jansen TL, Kallenberg CG, Spoorenberg A.

Arthritis Res Ther. 2011 Jun 20;13(3):R94. doi: 10.1186/ar3369.

PMID:
21689401
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation.

McLeod C, Bagust A, Boland A, Dagenais P, Dickson R, Dundar Y, Hill RA, Jones A, Mujica Mota R, Walley T.

Health Technol Assess. 2007 Aug;11(28):1-158, iii-iv. Review.

PMID:
17651658
[PubMed - indexed for MEDLINE]
Free Article
4.

Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor alpha blockers in ankylosing spondylitis.

Rudwaleit M, Listing J, Brandt J, Braun J, Sieper J.

Ann Rheum Dis. 2004 Jun;63(6):665-70. Epub 2004 Mar 22.

PMID:
15037444
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Investigation of effects of two-different treatment modalities on nerve conduction in patients with ankylosing spondylitis.

Capkin E, Karkucak M, Kose MM, Çakmak VA, Turkyilmaz AK, Tosun M.

Rheumatol Int. 2012 Feb;32(2):431-4. doi: 10.1007/s00296-010-1677-x. Epub 2010 Dec 1.

PMID:
21120488
[PubMed - indexed for MEDLINE]
6.

Remission in ankylosing spondylitis treated with anti-TNF-α drugs: a national multicentre study.

Spadaro A, Lubrano E, Marchesoni A, D'Angelo S, Ramonda R, Addimanda O, Perrotta FM, Olivieri I, Punzi L, Salvarani C.

Rheumatology (Oxford). 2013 Oct;52(10):1914-9. doi: 10.1093/rheumatology/ket249. Epub 2013 Jul 22.

PMID:
23878312
[PubMed - indexed for MEDLINE]
7.

Effectiveness, safety, and predictors of good clinical response in 1250 patients treated with adalimumab for active ankylosing spondylitis.

Rudwaleit M, Claudepierre P, Wordsworth P, Cortina EL, Sieper J, Kron M, Carcereri-De-Prati R, Kupper H, Kary S.

J Rheumatol. 2009 Apr;36(4):801-8. doi: 10.3899/jrheum.081048. Epub 2009 Feb 27.

PMID:
19273449
[PubMed - indexed for MEDLINE]
8.

Anti-TNF-alpha therapy for ankylosing spondylitis.

Son JH, Cha SW.

Clin Orthop Surg. 2010 Mar;2(1):28-33. doi: 10.4055/cios.2010.2.1.28. Epub 2010 Feb 4.

PMID:
20190998
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

Effectiveness and safety of adalimumab in patients with ankylosing spondylitis or psoriatic arthritis and history of anti-tumor necrosis factor therapy.

Rudwaleit M, Van den Bosch F, Kron M, Kary S, Kupper H.

Arthritis Res Ther. 2010;12(3):R117. doi: 10.1186/ar3054. Epub 2010 Jun 16.

PMID:
20553600
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

Erythrocyte sedimentation rate, C-reactive protein level, and serum amyloid a protein for patient selection and monitoring of anti-tumor necrosis factor treatment in ankylosing spondylitis.

de Vries MK, van Eijk IC, van der Horst-Bruinsma IE, Peters MJ, Nurmohamed MT, Dijkmans BA, Hazenberg BP, Wolbink GJ.

Arthritis Rheum. 2009 Nov 15;61(11):1484-90. doi: 10.1002/art.24838.

PMID:
19877087
[PubMed - indexed for MEDLINE]
Free Article
11.

Body mass does not affect the remission of psoriatic arthritis patients on anti-TNF-α therapy.

Iannone F, Fanizzi R, Scioscia C, Anelli MG, Lapadula G.

Scand J Rheumatol. 2013;42(1):41-4. doi: 10.3109/03009742.2012.715186. Epub 2012 Sep 20.

PMID:
22991950
[PubMed - indexed for MEDLINE]
12.

Real life experience confirms sustained response to long-term biologics and switching in ankylosing spondylitis.

Coates LC, Cawkwell LS, Ng NW, Bennett AN, Bryer DJ, Fraser AD, Emery P, Marzo-Ortega H.

Rheumatology (Oxford). 2008 Jun;47(6):897-900. doi: 10.1093/rheumatology/ken094. Epub 2008 Apr 10.

PMID:
18403400
[PubMed - indexed for MEDLINE]
Free Article
13.

Responsiveness of the Ankylosing Spondylitis Disease Activity Score (ASDAS) and clinical and MRI measures of disease activity in a 1-year follow-up study of patients with axial spondyloarthritis treated with tumour necrosis factor alpha inhibitors.

Pedersen SJ, Sørensen IJ, Hermann KG, Madsen OR, Tvede N, Hansen MS, Thamsborg G, Andersen LS, Majgaard O, Loft AG, Erlendsson J, Asmussen K, Johansen JS, Jurik AG, Møller J, Hasselquist M, Mikkelsen D, Skjødt T, Hansen A, Ostergaard M.

Ann Rheum Dis. 2010 Jun;69(6):1065-71. doi: 10.1136/ard.2009.111187. Epub 2009 Sep 9.

PMID:
19740906
[PubMed - indexed for MEDLINE]
14.

Sick leave in patients with ankylosing spondylitis before and after anti-TNF therapy: a population-based cohort study.

Kristensen LE, Petersson IF, Geborek P, Jöud A, Saxne T, Jacobsson LT, Englund M.

Rheumatology (Oxford). 2012 Feb;51(2):243-9. doi: 10.1093/rheumatology/ker169. Epub 2011 May 12.

PMID:
21565900
[PubMed - indexed for MEDLINE]
Free Article
15.

Etanercept 25 mg/week is effective enough to maintain remission for ankylosing spondylitis among Korean patients.

Lee SH, Lee YA, Hong SJ, Yang HI.

Clin Rheumatol. 2008 Feb;27(2):179-81. Epub 2007 Sep 15.

PMID:
17874173
[PubMed - indexed for MEDLINE]
16.

[Effects of infliximab and etanercept, two types of anti-tumor necrosis factor-alpha inhibitor on serum level of matrix metalloproteinase 3 expression in patients with ankylosing spondylitis].

Yang CH, Huang F, Deng XH, Zhang JL, Zhang LY, Guo JH, Liang DF, Wang LS, Zhang YM.

Zhonghua Yi Xue Za Zhi. 2006 Sep 19;86(35):2451-4. Chinese.

PMID:
17156669
[PubMed - indexed for MEDLINE]
17.

Efficacy of antitumor necrosis factor(α) agents on patients with ankylosing spondylitis.

Ren L, Li J, Luo R, Tang R, Zhu S, Wan L.

Am J Med Sci. 2013 Dec;346(6):455-61. doi: 10.1097/MAJ.0b013e3182926a23. Review.

PMID:
23715113
[PubMed - indexed for MEDLINE]
18.

Human leukocyte antigen-G in ankylosing spondylitis and the response after tumour necrosis factor-alpha blocker therapy.

Chen CH, Liao HT, Chen HA, Liu CH, Liang TH, Wang CT, Tsai CY, Chou CT.

Rheumatology (Oxford). 2010 Feb;49(2):264-70. doi: 10.1093/rheumatology/kep360. Epub 2009 Dec 11.

PMID:
20008091
[PubMed - indexed for MEDLINE]
Free Article
19.

Reproducibility of the Bath Ankylosing Spondylitis Indices of disease activity (BASDAI), functional status (BASFI) and overall well-being (BAS-G) in anti-tumour necrosis factor-treated spondyloarthropathy patients.

Madsen OR, Rytter A, Hansen LB, Suetta C, Egsmose C.

Clin Rheumatol. 2010 Aug;29(8):849-54. doi: 10.1007/s10067-010-1407-5. Epub 2010 Mar 21.

PMID:
20306214
[PubMed - indexed for MEDLINE]
20.

Predictors of treatment response and drug continuation in 842 patients with ankylosing spondylitis treated with anti-tumour necrosis factor: results from 8 years' surveillance in the Danish nationwide DANBIO registry.

Glintborg B, Ostergaard M, Krogh NS, Dreyer L, Kristensen HL, Hetland ML.

Ann Rheum Dis. 2010 Nov;69(11):2002-8. doi: 10.1136/ard.2009.124446. Epub 2010 May 28.

PMID:
20511613
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk